Home › Companies › Rapport Therapeutics, Inc. › 2025-2026
At Rapport Therapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 59 asset managers reported how they voted in their SEC Form N-PX filings, covering 663 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To ratify the appointment of PricewaterhouseCoopers LLP as Rapport's independent registered… — Rapport Therapeutics, Inc.'s filing reports the proposal as approved, with 99.8% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Rapport Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Rapport Therapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 10, 2026: 4 items on Rapport Therapeutics, Inc.’s Form 8-K, filed June 10, 2026: 1 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Rapport Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Rapport Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: James Healy, M.D., Ph.D. | 41,762,713 | -- | -- | 587,163 | 1,983,035 | 99% | Not verified | — |
| Elect Director: Robert J. Perez | 37,592,089 | -- | -- | 4,757,787 | 1,983,035 | 89% | Not verified | — |
| Elect Director: Raymond Sanchez, M.D. | 41,754,131 | -- | -- | 595,745 | 1,983,035 | 99% | Not verified | — |
| 2. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm | 44,255,547 | 57,445 | 19,919 | -- | -- | 99.8% | Approved | — |
Source: Rapport Therapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
Each item below shows how the 59 asset managers that disclosed a Rapport Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Rapport Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
99.5% of fund votes cast · no official result
Description as filed by funds: To elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II Directors: James Healy, M.D., Ph.D.
The 40 asset managers below reported 11,423,863 for, 47,405 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,321,293 | 0 | 0 | 0 | For |
| Capital Group | 3,356,033 | 0 | 0 | 0 | For |
| Vanguard | 1,624,817 | 0 | 0 | 0 | For |
| T. Rowe Price | 985,595 | 0 | 0 | 0 | For |
| AllianceBernstein | 391,628 | 0 | 0 | 0 | For |
| State Street | 138,433 | 0 | 0 | 0 | For |
| Invesco | 124,302 | 0 | 0 | 0 | For |
| Principal | 87,582 | 0 | 0 | 0 | For |
| Equitable | 75,648 | 0 | 0 | 0 | For |
| TIAA | 68,190 | 0 | 0 | 0 | For |
| American Century | 55,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 50,591 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 44,109 | Withhold |
| ALPS ETF Trust | 38,907 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,927 | 0 | 0 | 0 | For |
| Lincoln Financial | 18,800 | 0 | 0 | 0 | For |
| Northern Trust | 13,174 | 0 | 0 | 0 | For |
| ProShares | 11,407 | 0 | 0 | 0 | For |
| Pacific Life | 11,090 | 0 | 0 | 0 | For |
| AQR | 5,069 | 0 | 0 | 0 | For |
| Allspring | 4,502 | 0 | 0 | 0 | For |
| DWS | 4,080 | 0 | 0 | 0 | For |
| Victory Capital | 3,354 | 0 | 0 | 0 | For |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 3,296 | Withhold |
| Brighthouse | 2,814 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
99.5% of fund votes cast · no official result
Description as filed by funds: To elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II Directors: Raymond Sanchez, M.D.
The 40 asset managers below reported 11,423,863 for, 47,405 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,321,293 | 0 | 0 | 0 | For |
| Capital Group | 3,356,033 | 0 | 0 | 0 | For |
| Vanguard | 1,624,817 | 0 | 0 | 0 | For |
| T. Rowe Price | 985,595 | 0 | 0 | 0 | For |
| AllianceBernstein | 391,628 | 0 | 0 | 0 | For |
| State Street | 138,433 | 0 | 0 | 0 | For |
| Invesco | 124,302 | 0 | 0 | 0 | For |
| Principal | 87,582 | 0 | 0 | 0 | For |
| Equitable | 75,648 | 0 | 0 | 0 | For |
| TIAA | 68,190 | 0 | 0 | 0 | For |
| American Century | 55,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 50,591 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 44,109 | Withhold |
| ALPS ETF Trust | 38,907 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,927 | 0 | 0 | 0 | For |
| Lincoln Financial | 18,800 | 0 | 0 | 0 | For |
| Northern Trust | 13,174 | 0 | 0 | 0 | For |
| ProShares | 11,407 | 0 | 0 | 0 | For |
| Pacific Life | 11,090 | 0 | 0 | 0 | For |
| AQR | 5,069 | 0 | 0 | 0 | For |
| Allspring | 4,502 | 0 | 0 | 0 | For |
| DWS | 4,080 | 0 | 0 | 0 | For |
| Victory Capital | 3,354 | 0 | 0 | 0 | For |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 3,296 | Withhold |
| Brighthouse | 2,814 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
93% of fund votes cast · no official result
The 40 asset managers below reported 10,704,995 for, 766,273 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,321,293 | 0 | 0 | 0 | For |
| Capital Group | 3,356,033 | 0 | 0 | 0 | For |
| Vanguard | 1,624,817 | 0 | 0 | 0 | For |
| T. Rowe Price | 985,595 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 391,628 | Withhold |
| State Street | 138,330 | 0 | 0 | 103 | For |
| Invesco | 124,302 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 87,582 | Withhold |
| Equitable | 57,598 | 0 | 0 | 18,050 | Mixed |
| TIAA | 0 | 0 | 0 | 68,190 | Withhold |
| American Century | 0 | 0 | 0 | 55,500 | Withhold |
| Goldman Sachs | 50,591 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 44,109 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 38,907 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 20,927 | Withhold |
| Lincoln Financial | 18,800 | 0 | 0 | 0 | For |
| Northern Trust | 13,174 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 11,407 | Withhold |
| Pacific Life | 11,090 | 0 | 0 | 0 | For |
| AQR | 0 | 0 | 0 | 5,069 | Withhold |
| Allspring | 0 | 0 | 0 | 4,502 | Withhold |
| DWS | 0 | 0 | 0 | 4,080 | Withhold |
| Victory Capital | 0 | 0 | 0 | 3,354 | Withhold |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 3,296 | Withhold |
| Brighthouse | 0 | 0 | 0 | 2,814 | Withhold |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Elect James I. Healy
Rapport Therapeutics, Inc.’s own tally for this item (“Elect Director: James Healy, M.D., Ph.D.”): 41,762,713 for, 587,163 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 1,424,894 for, 16,706 withheld, 6,002 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 988,665 | 0 | 0 | 0 | For |
| Charles Schwab | 240,237 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 44,705 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 33,399 | 0 | 0 | 0 | For |
| Prudential/PGIM | 24,700 | 0 | 0 | 0 | For |
| John Hancock | 23,150 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 16,706 | Withhold |
| Advisor Managed Portfolios | 14,656 | 0 | 0 | 0 | For |
| Global X | 13,758 | 0 | 0 | 0 | For |
| Russell Investments | 13,075 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 6,438 | 0 | 0 | 0 | For |
| Vanguard | 6,297 | 0 | 1 | 0 | For |
| Jackson National | 0 | 0 | 6,001 | 0 | Abstain |
| SEI | 5,200 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 3,482 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 2,181 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 2,130 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 1,400 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 831 | 0 | 0 | 0 | For |
| Nationwide | 419 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 171 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: DIRECTOR: RAYMOND SANCHEZ, M.D.
Rapport Therapeutics, Inc.’s own tally for this item (“Elect Director: Raymond Sanchez, M.D.”): 41,754,131 for, 595,745 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 1,424,894 for, 16,706 withheld, 6,002 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 988,665 | 0 | 0 | 0 | For |
| Charles Schwab | 240,237 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 44,705 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 33,399 | 0 | 0 | 0 | For |
| Prudential/PGIM | 24,700 | 0 | 0 | 0 | For |
| John Hancock | 23,150 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 16,706 | Withhold |
| Advisor Managed Portfolios | 14,656 | 0 | 0 | 0 | For |
| Global X | 13,758 | 0 | 0 | 0 | For |
| Russell Investments | 13,075 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 6,438 | 0 | 0 | 0 | For |
| Vanguard | 6,297 | 0 | 1 | 0 | For |
| Jackson National | 0 | 0 | 6,001 | 0 | Abstain |
| SEI | 5,200 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 3,482 | 0 | 0 | 0 | For |
| Innovator ETFs Trust | 2,181 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 2,130 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 1,400 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 831 | 0 | 0 | 0 | For |
| Nationwide | 419 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 171 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: DIRECTOR: ROBERT J. PEREZ
Rapport Therapeutics, Inc.’s own tally for this item (“Elect Director: Robert J. Perez”): 37,592,089 for, 4,757,787 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 1,350,622 for, 58,599 withheld, 38,380 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 988,665 | 0 | 0 | 0 | For |
| Charles Schwab | 240,237 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 44,705 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 13,356 | 0 | 20,043 | 0 | Mixed |
| Prudential/PGIM | 24,700 | 0 | 0 | 0 | For |
| John Hancock | 15,136 | 0 | 8,014 | 0 | Mixed |
| Brighthouse | 0 | 0 | 0 | 16,706 | Withhold |
| Advisor Managed Portfolios | 14,656 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 13,758 | Withhold |
| Russell Investments | 0 | 0 | 0 | 13,075 | Withhold |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 6,438 | Withhold |
| Vanguard | 4,996 | 0 | 9 | 1,292 | Mixed |
| Jackson National | 0 | 0 | 6,001 | 0 | Abstain |
| SEI | 0 | 0 | 0 | 5,200 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 3,482 | 0 | Abstain |
| Innovator ETFs Trust | 2,181 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 0 | 0 | 0 | 2,130 | Withhold |
| TARGET PORTFOLIO TRUST | 1,400 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 0 | 0 | 831 | 0 | Abstain |
| Nationwide | 419 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 171 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Rapport's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Rapport Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 44,255,547 for, 57,445 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of PwC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 12,908,345 for, 16,706 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,321,293 | 0 | 0 | 0 | For |
| Capital Group | 3,356,033 | 0 | 0 | 0 | For |
| Vanguard | 1,631,115 | 0 | 0 | 0 | For |
| BlackRock | 988,665 | 0 | 0 | 0 | For |
| T. Rowe Price | 985,595 | 0 | 0 | 0 | For |
| AllianceBernstein | 391,628 | 0 | 0 | 0 | For |
| Charles Schwab | 240,237 | 0 | 0 | 0 | For |
| State Street | 138,433 | 0 | 0 | 0 | For |
| Invesco | 124,302 | 0 | 0 | 0 | For |
| Principal | 87,582 | 0 | 0 | 0 | For |
| Equitable | 75,648 | 0 | 0 | 0 | For |
| TIAA | 68,190 | 0 | 0 | 0 | For |
| American Century | 55,500 | 0 | 0 | 0 | For |
| Goldman Sachs | 50,591 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 44,705 | 0 | 0 | 0 | For |
| Dimensional | 44,109 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 38,907 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 33,399 | 0 | 0 | 0 | For |
| Prudential/PGIM | 24,700 | 0 | 0 | 0 | For |
| John Hancock | 23,150 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,927 | 0 | 0 | 0 | For |
| Brighthouse | 2,814 | 0 | 16,706 | 0 | Mixed |
| Lincoln Financial | 18,800 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 14,656 | 0 | 0 | 0 | For |
| Global X | 13,758 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 47,826,929 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.04% |
| 2 | Capital Group | 7.02% |
| 3 | Vanguard | 3.41% |
| 4 | BlackRock | 2.07% |
| 5 | T. Rowe Price | 2.06% |
| 6 | AllianceBernstein | 0.82% |
| 7 | Charles Schwab | 0.50% |
| 8 | State Street | 0.29% |
| 9 | Invesco | 0.26% |
| 10 | Principal | 0.18% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Keel Point, LLC | <0.01% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Third Rock Ventures | 16.95% | DEF14A |
| FMR (Fidelity) | 14.99% | 13F |
| Third Rock Ventures V, L.P. | 13.13% | 13G |
| Entities affiliated with Fidelity | 11.47% | DEF14A |
| ARCH Venture Fund XII, L.P. | 7.80% | DEF14A |
| Capital International | 6.48% | 13F |
| Entities affiliated with Cormorant Asset Management, LP | 6.33% | DEF14A |
| Goldman Sachs | 6.15% | 13F |
| Cormorant Asset Management, LP | 5.56% | 13G |
| One or more entities advised by Capital Research and Management Company | 5.44% | DEF14A |
Percentages above are of 47,826,929 shares outstanding, as reported by Rapport Therapeutics, Inc. on its Form 10-Q dated May 4, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Rapport Therapeutics, Inc.’s 10-Q dated May 4, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Rapport Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Rapport Therapeutics (RAPP) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/rapport-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.